Cronos Group Inc.

Company Overview

Cronos Group, formerly known as PharmaCan Capital Corp., is a vertically integrated cannabis company with great geographical diversification as the foundation for growth across both medicinal and recreational marijuana.

With solid quarter on quarter growth of nearly 100% in the last quarter, Cronos is also preparing for the future by expanding its current production capacity and targeting strategic growth in booming medicinal markets such as Germany.

Cronos has the pieces to stay competitive in the cannabis market, proven by their partnerships, competitive oilbased products, and growing operations in Canada and Israel (a facility that will produce cannabis at very low cost).

Management Overview

Michael Gorenstein -CEO & Chairman

Mr. Gorenstein is a partner at Alphabet Ventures LLC, a multi-strategy investment management firm located in New York City. Prior to Alphabet Management, Michael was the VP and General Counsel of Saiers Capital LLC and a corporate attorney at Sullivan & Cromwell where he focused on Mergers and Acquisitions and Capital Market transactions.

Michael graduated from the University of Pennsylvania Law School with a JD, the Wharton School at University of Pennsylvania with a certificate in BEPP and the Kelley School of Business at Indiana University with a BSB in Finance.

David Hsu - Chief Operating Officer

Prior to joining Cronos, Hsu spent over 10 years with Deloitte/CRG Partners, a premier turnaround consulting firm where he operated and managed distressed companies with revenues in excess of $500M+.

His expertise includes financial and operational restructuring, growth creation, and lean manufacturing gleaned from experience working in various sectors including consumer packaged goods, manufacturing, distribution, media, and transportation. David graduated from Babson College

with a Bachelor of Science in Business Management and is a certified Lean Six Sigma Black Belt.

William Hilson - Chief Financial Officer

Mr. Hilson is a Certified Public Accountant (CPA) and has spent over 15 years as regional CFO for two publicly listed multinational pharmaceutical companies – Merck KGaA and Serono S.A. His expertise includes financial operations, strategy, performance management, sales & marketing, clinical trial management, international tax, debt & equity financing; including a NASDAQ initial public offering.

Prior to joining Cronos Group, William was also involved in a number of mergers & acquisitions and licensing deals in the pharmaceutical sector. He earned his CPA designation while working at a Toronto firm specialising in tax structure.

He graduated from the University of Toronto and The University of Western Ontario where he earned a Master of Science degree in Clinical Biochemistry and an Honours Bachelor of Genetics.

Company Analysis

The American cannabis industry has received the true-crime treatment with the release of Netflix’s captivating new docu-series, Murder Mountain. Over the course of six episodes, the series traces the disappearance of a Southern Californian man, Garret Rodriguez, who vanished while working on a cannabis farm in Humboldt County. The area...
The week's big winners were Canopy Growth (NYSE:CGC) up 13.82% on the back of their entry into the US Hemp market, Australian Cann Group - on significantly higher volume - traded 12.68% up and Grow Generation traded almost 10% up. The week's big losers were KushCo Holdings, 23% down, on...
2018 was a trailblazing year for the cannabis industry. The Australian government gave the legislative green light to marijuana exports, which many experts saw as a move to dominate the international market. A study conducted by New Frontier Data also estimated that the potential size of Australia’s nascent local cannabis...